Progressive muscular atrophy

Epidemiology and onset

PMA is rare among MNDs and has been estimated to represent a small percentage of cases. Onset most often occurs in adulthood, frequently in middle or later adult life, although presentations vary. The course is usually slower than typical ALS for many patients, but an important minority develop upper motor neuron signs over time and are reclassified.

Pathology and investigations

Pathologically, PMA reflects loss of anterior horn cells in the spinal cord and motor nuclei in the brainstem. Diagnosis relies on clinical history and examination plus electrodiagnostic testing. Electromyography (EMG) typically shows chronic and active denervation in multiple regions, while nerve conduction studies help exclude primary peripheral neuropathies. Magnetic resonance imaging (MRI) of the brain and spinal cord and selected blood or genetic tests are used to exclude structural, inflammatory or metabolic mimics.

Clinical features and differential diagnosis

• Insidious weakness, often beginning in one limb or distribution
• Muscle wasting, fasciculations and cramps
• Diminished or absent deep tendon reflexes in affected areas
• Relative absence of spasticity or brisk reflexes early on

Conditions to consider include multifocal motor neuropathy, spinal muscular atrophy variants, motor-predominant peripheral neuropathies and structural lesions compressing motor roots.

Prognosis and course

The natural history of PMA varies. Many patients experience a slower decline than is typical for ALS, and some maintain substantial function for years. Nonetheless, respiratory muscle weakness and bulbar involvement can occur, and conversion to ALS with emerging upper motor neuron signs is well recognised. Regular monitoring of respiratory function and nutritional status is important.

Management

There is no cure specific to PMA. Management emphasises multidisciplinary supportive care: physiotherapy and occupational therapy to preserve mobility and function; assistive devices and home adaptations; symptomatic treatment of cramps, pain and secretions; nutritional support and interventions for swallowing difficulty; and respiratory monitoring with timely consideration of noninvasive ventilation. Medications used in other MNDs may be discussed with patients, but evidence specific to PMA is limited.

Research and considerations

Research into the causes, biomarkers and treatments for motor neuron diseases continues. Genetic contributions are recognised in some families across the MND spectrum, but most PMA cases are sporadic. Longitudinal assessment is essential because early presentation can evolve, and management plans should be regularly reviewed and personalised.